News
RARE
--
0.00%
--
New Strong Sell Stocks for June 18th
Zacks.com · 9h ago
Premarket Movers: Novavax, Blue Owl Capital, Olo
marketwatch.com · 4d ago
Insider Trends: Selling By Insiders Lingers at Ultragenyx Pharmaceutical
MT Newswires · 06/11 21:13
Ultragenyx on go with GTX-102 study for angelman syndrome in U.K.
GeneTx Biotherapeutics and Ultragenyx Pharmaceutical (RARE) announces that the U.K. Medicines and Healthcare Products Regulatory Agency ((MHRA)) has approved the Clinical Trial Application ((CTA)) for the Phase 1/2 study of
Seekingalpha · 06/10 12:56
GeneTx and Ultragenyx Receive Approval From UK MHRA To Begin Clinical Study Of GTX-102 For The Treatment Of Angelman Syndrome
GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), companies partnered in the development of intrathecally administered GTX-102, an investigational treatment for Angelman syndrome, today
Benzinga · 06/10 12:39
BRIEF-Genetx And Ultragenyx Receive Approval From U.K. Regulatory Agency To Begin Clinical Study Of Gtx-102 For The Treatment Of Angelman Syndrome
reuters.com · 06/10 12:39
GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome
Patient enrollment to begin in early second half of 2021 in U.K. and Canada
GlobeNewswire · 06/10 12:30
Ultragenyx to Move Forward With Phase 1/2 Trial of GTX-102 in Angelman Syndrome
MT Newswires · 06/10 10:08
Baird Starts Ultragenyx Pharmaceutical at Neutral with $109 Price Target
MT Newswires · 06/04 10:57
Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's...
GlobeNewswire · 06/03 20:01
Ultragenyx (RARE) Down 7.8% Since Last Earnings Report: Can It Rebound?
Zacks.com · 06/03 15:31
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shareholders Booked A 40% Gain In The Last Five Years
Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) shareholders might be concerned after seeing the share price drop 16% in...
Simply Wall St. · 06/02 10:02
Ultragenyx to Present at Jefferies Virtual Healthcare Conference
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's...
GlobeNewswire · 05/26 12:31
Biotech M&A could soon pick up following slow 2021 start - Jefferies
Biotech M&A, which has been relatively quiet so far this year, is poised to pick up due to more reasonable prices for biotech companies, according to Jefferies analyst Michael Yee."Typically,
Seekingalpha · 05/23 19:25
Drug pricing in focus at Citi, 1Life earns another bull at Keybanc, and more in today’s analyst action
Buy Dexcom, Abiomed, and Eargo on the dip: William BlairDexCom (DXCM), Abiomed (ABMD), and Eargo (EAR) have underperformed in the year so far, but citing their quarterly reports, William Blair’s
Seekingalpha · 05/21 12:45
Biotech M&A Has Been Slow This Year. Why It Might Get Busier.
Biotech stocks have suffered through a months-long rout that have made prices cheaper for acquirers, a Jefferies analyst writes.
marketwatch.com · 05/21 12:30
GeneTx Bio-Ultragenyx's Angelman Syndrome Study To Start Enrollment In Canada
Benzinga · 05/19 19:23
BRIEF-Genetx And Ultragenyx Receive Clearance From Health Canada To Begin Clinical Study Of Gtx-102 In Canada For The Treatment Of Angelman Syndrome
reuters.com · 05/19 13:16
Ultragenyx and GeneTx get Health Canada clearance for GTX-102 neurogenetic disorder study
Ultragenyx Pharmaceutical (RARE) and GeneTx Biotherapeutics have received clearance from Health Canada to begin enrollment in the Phase 1/2 study of GTX-102 in pediatric patients with Angelman syndrome in Canada.Angelman syndrome
Seekingalpha · 05/19 12:41
GeneTx and Ultragenyx Receive Clearance from Health Canada to Begin Clinical Study of GTX-102 in Canada for the Treatment of Angelman Syndrome
GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of intrathecally administered GTX-102, an investigational treatment for Angelman syndrome, today announced that they have received clearanc...
GlobeNewswire · 05/19 12:30
Webull provides a variety of real-time RARE stock news. You can receive the latest news about Ultragenyx through multiple platforms. This information may help you make smarter investment decisions.
About RARE
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.